Boron Neutron Capture Therapy and Nanotechnology

RadioNano Therapeutics Inc. focuses on developing innovative therapeutic solutions that leverage the unique properties of radioisotopes and nanotechnology. Their primary technology involves the use of targeted radioisotope delivery systems, which are designed to enhance the precision of cancer treatment. By utilizing nanoparticles to deliver radioactive isotopes directly to tumor cells, the company aims to minimize damage to surrounding healthy tissues while maximizing the therapeutic effect on cancerous cells. This targeted approach not only improves treatment efficacy but also reduces side effects commonly associated with conventional radiation therapies.

In addition to their targeted delivery systems, RadioNano Therapeutics is also exploring the potential of combination therapies that integrate their radioisotope technology with other treatment modalities. This includes the use of immunotherapy and chemotherapy, which may work synergistically to improve patient outcomes. The company is committed to advancing its pipeline of products through rigorous scientific research and clinical trials, with the goal of providing more effective and less invasive treatment options for patients suffering from various types of cancer.

Japan

RadioNano Therapeutics, a venture company, was established with the support of Kyoto University Innovation Capital Co. Ltd. for the social implementation of Boron Neutron Capture Therapy (BNCT) using highly hydrophilic boron-containing inorganic nanoparticles developed by Professor Naoki Komatsu of the Graduate School of Human and Environmental Studies, Kyoto University and Professor Minoru Suzuki of the Institute for Composite Nuclear Science, Kyoto University.

RadioNano Therapeutics Inc.

Company Details